Britain's GSK and drug developer iTeos Therapeutics said on Tuesday they have stopped developing an experimental lung cancer ...

GSK Plc and iTeos Therapeutics ended the development of an experimental lung cancer drug, the latest in a series of setbacks ...

(Reuters) -iTeos Therapeutics and partner GSK said on Tuesday they have terminated development of their experimental lung ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are ...

On the back of strong numbers, Anil Singhvi recommends a slew of stocks to buy including Dalmia Bharat Sugar, ASK Automotive, ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

Our writer can see the appeal of this recently popular dividend stock from the FTSE 100 index. But will he buy it for his own ...

GSK Pharma reports 35 per cent YoY rise in Q4FY25 profit led by gains in general medicines and vaccines; oncology launches ...

GlaxoSmithKline Pharmaceuticals, the Indian arm of UK-based GSK, reported a 35% year-on-year jump in consolidated net profit ...

Andrew Witty — who became UnitedHealth Group’s CEO in 2021 — is stepping down from the top post due to personal reasons after ...

Teos Therapeutics, Inc. (NASDAQ:ITOS) reported topline results from an updated interim analysis of the GALAXIES Lung-201 ...